← Back to Search

Financial Incentives for Quitting Smoking (FIESTA II Trial)

N/A
Waitlist Available
Led By Joseph Ladapo, MD, PhD
Research Sponsored by University of California, Los Angeles
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
can provide consent in English or Spanish
age ≥ 18 years
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 years
Awards & highlights

FIESTA II Trial Summary

This trial is testing whether financial incentives can help smokers quit, by comparing three different approaches. They will also compare how well these approaches work in the short term and long term, and whether they are a good investment.

Who is the study for?
This trial is for adults over 18 who have smoked tobacco in the last month, are considering quitting smoking, and can consent in English or Spanish. They must have an active U.S. phone number and address. It's not for those using only smokeless tobacco, pregnant or breastfeeding individuals, people discharged to institutions like nursing homes, or anyone unable to consent.Check my eligibility
What is being tested?
The study tests if financial rewards can help hospitalized smokers quit. Participants will receive smoking cessation counseling (Quitline), pharmacotherapy (like nicotine patches), and cash incentives for quitting or using these therapies effectively.See study design
What are the potential side effects?
There may be no direct medical side effects from participating; however, common challenges when quitting smoking include nicotine withdrawal symptoms such as irritability, cravings, difficulty concentrating, increased appetite leading to weight gain.

FIESTA II Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I can give my consent in English or Spanish.
Select...
I am 18 years old or older.
Select...
I am 18 years old or older.
Select...
I can give my consent in English or Spanish.
Select...
I am considering quitting smoking.
Select...
I am considering quitting smoking.

FIESTA II Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Smoking abstinence assessed by self-report and biochemically verified by salivary cotinine
Secondary outcome measures
Long term return on investment of using financial incentives to promote smoking cessation (Cost analysis)
Quality of life as measured by PROMIS-29 Profile v2.0
Short term return on investment of using financial incentives to promote smoking cessation (Cost analysis)
+1 more

FIESTA II Trial Design

3Treatment groups
Experimental Treatment
Group I: Outcome-Based IncentivesExperimental Treatment3 Interventions
Group II: Goal-Directed IncentivesExperimental Treatment3 Interventions
Group III: Enhanced Usual CareExperimental Treatment2 Interventions
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Smoking cessation counseling (Quitline)
2015
N/A
~190
Smoking cessation pharmacotherapy (e.g, nicotine replacement therapy)
2015
N/A
~190

Find a Location

Who is running the clinical trial?

University of California, Los AngelesLead Sponsor
1,521 Previous Clinical Trials
10,277,878 Total Patients Enrolled
NYU Langone HealthOTHER
1,358 Previous Clinical Trials
815,755 Total Patients Enrolled
Olive View-UCLA Education & Research InstituteOTHER
33 Previous Clinical Trials
878,956 Total Patients Enrolled

Media Library

Smoking cessation pharmacotherapy Clinical Trial Eligibility Overview. Trial Name: NCT03979885 — N/A
Quitting Smoking Research Study Groups: Goal-Directed Incentives, Outcome-Based Incentives, Enhanced Usual Care
Quitting Smoking Clinical Trial 2023: Smoking cessation pharmacotherapy Highlights & Side Effects. Trial Name: NCT03979885 — N/A
Smoking cessation pharmacotherapy 2023 Treatment Timeline for Medical Study. Trial Name: NCT03979885 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is there still availability for participants in this research?

"This clinical trial is not currently recruiting patients, as evidenced by the data listed on clinicialtrials.gov from its original posting date of January 6th 2020 and most recent edit taking place a few days ago on May 1st 2022. Despite this, 163 other studies are still actively enrolling participants at present."

Answered by AI

Who else is applying?

What state do they live in?
New York
What portion of applicants met pre-screening criteria?
Did not meet criteria
What site did they apply to?
David Geffen School of Medicine
~205 spots leftby Mar 2025